Patents by Inventor Suet Chung Yeung
Suet Chung Yeung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11021467Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A?, B?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: June 1, 2021Assignee: Gilead Sciences, Inc.Inventors: Shaopei Cai, Zhimin Du, Musong Kim, Jennifer A. Loyer-Drew, Devan Naduthambi, Leena Patel, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer Anne Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Patent number: 10308639Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein X, Y, Z, n, m?, A?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: June 4, 2019Assignee: Gilead Sciences, Inc.Inventors: Jerry Evarts, Joshua Kaplan, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Jennifer A. Treiberg, Suet Chung Yeung
-
Patent number: 10221197Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A?, W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: March 5, 2019Assignee: Gilead Sciences, Inc.Inventors: Zhimin Du, Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer A. Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Patent number: 10092563Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: October 9, 2018Assignee: Gilead Sciences, Inc.Inventors: Shaopei Cai, Zhimin Du, Joshua Kaplan, Jennifer A. Loyer-Drew, Devan Naduthambi, Barton W. Phillips, Gary Phillips, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Patent number: 9951065Abstract: The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R1, R2a, R2b, Rn, Rm, and Rt are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.Type: GrantFiled: May 12, 2016Date of Patent: April 24, 2018Assignee: Gilead Sciences, Inc.Inventors: Mark J. Bartlett, Julian Andrew Codelli, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna Elbel, Jennifer Alissa Loyer-Drew, David Sperandio, Joshua Van Veldhuizen, Hai Yang, Suet Chung Yeung
-
Patent number: 9499523Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, m, R1, R2, R3, R4, and R5 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: November 22, 2016Assignee: GILEAD SCIENCES, INC.Inventors: Musong Kim, Stephane Perreault, Suet Chung Yeung
-
Publication number: 20160333009Abstract: The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R1, R2a, R2b, Rn, Rm, and Rt are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.Type: ApplicationFiled: May 12, 2016Publication date: November 17, 2016Inventors: Mark J. Bartlett, Julian Andrew Codelli, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna Elbel, Jennifer Alissa Loyer-Drew, David Sperandio, Joshua Van Veldhuizen, Hai Yang, Suet Chung Yeung
-
Publication number: 20150361070Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein X, Y, Z, n, m?, A?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Jerry Evarts, Joshua Kaplan, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Jennifer A. Treiberg, Suet Chung Yeung
-
Publication number: 20150361071Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, m, R1, R2, R3, R4, and R5 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Musong Kim, Stephane Perreault, Suet Chung Yeung
-
Publication number: 20150361054Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Shaopei Cai, Zhimin Du, Joshua Kaplan, Jennifer A. Loyer-Drew, Devan Naduthambi, Barton W. Phillips, Gary Phillips, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Publication number: 20150361095Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A?, W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Zhimin Du, Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer A. Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Publication number: 20150361068Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A?, B?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Shaopei Cai, Zhimin Du, Musong Kim, Jennifer A. Loyer-Drew, Devan Naduthambi, Leena Patel, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer Anne Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung